Sir Stephen Philip Jackson, FRS, FMedSci (born 17 July 1962) is the Frederick James Quick Professor of Biology.

[2] Following his PhD, Jackson carried out postdoctoral research with Robert Tjian at the University of California, Berkeley, where he developed an interest in the regulation of transcription.

[5][6][7] In 1997 Jackson founded KuDOS Pharmaceuticals with the aim of translating knowledge of DNA damage response pathways into new treatments for cancer.

This time the first author was Abdeladim Moumen, and the paper 'hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage' was retracted from Cell.

Van Heck Prize (2015) for "his cardinal contributions related to cellular events that detect, signal the presence of and repair DNA damages".

[32] Jackson is the co-winner of the King Faisal International Prize for Science 2016, in recognition of his "outstanding contribution to defining the link between the basic mechanism of genomic DNA instability and its relationship to cancer.

[35] In 2016, Jackson was awarded the Dr A. H. Heineken Prize for Medicine[36] for his "fundamental research into DNA repair in human cells and for the successful application of knowledge of that process in the development of new cancer drugs".

[38] The Fondation ARC's Leopold Griffuel Prize in Translational and Clinical Research was presented to Jackson in 2019 for his work on DNA damage repair and his role in the development of medicines such as PARP1 and 2 inhibitors, currently used for cancer treatment.